The AASLD and IDSA HCV Guidance Panel has released updated guidelines
for the treatment of hepatitis C virus infection, according to newly
published data in Hepatology.
AASLD/IDSA HCV Guidance Panel. Hepatology. 2015;doi:10.1002/hep.27950.
“The goal of the hepatitis C guidance is to
provide up-to-date recommendations for HCV care practitioners on the
optimal screening, management, and treatment for adults with HCV
infection in the United States, using a rigorous review process to
evaluate the best available evidence,” the researchers wrote. “This
review provides a condensed summary of recommendations from the
The panel, which included HCV Next Editorial board members Arthur Y. Kim, MD, and Michael R. Charlton, MD, and HCV Next Co-Chief Editor Michael S. Saag, MD,
used an evidence-based approach to review available information for the
HCV guidance. Sources of information included peer-reviewed research;
FDA research and safety information on products; manufacturer
information; drug interaction data; prescribing information from
FDA-approved products; and more.
Key recommendations were outlined in various
topics: HCV testing and linkage to care, when and in whom to begin HCV
therapy, the initial treatment of HCV, treating unique patient
populations, HIV/HCV coinfection and acute HCV.
Download the Practice Guidance here (PDF)
Labels: AASLD/IDSA/IAS–USA Guidelines